Cellectis
Records under this name other than the patents Cellectis holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 98 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,000,746 | A Laglidadg Homing Endonuclease Cleaving the T Cell Receptor Alpha Gene and Uses Thereof now held by 2SEVENTY Bio, Inc. In force · High confidence | In force | High confidence | |
| US 10,006,052 | A Laglidadg Homing Endonuclease Cleaving the C-C Chemokine Receptor TYPE-5 (CCR5) Gene and Uses Thereof now held by 2SEVENTY Bio, Inc. In force · High confidence | In force | High confidence | |
| US 10,294,304 | Chimeric Antigen Receptors Targeting B-Cell Maturation Antigen conveyed to Pfizer Inc. In force · High confidence | In force | High confidence | |
| US 11,072,644 | Inhibitory Chimeric Antigen Receptors now held by Allogene Therapeutics, Inc. In force · High confidence | In force | High confidence | |
| US 11,312,782 | Chimeric Antigen Receptors Targeting B-Cell Maturation Antigen conveyed to Pfizer Inc. In force · High confidence | In force | High confidence | |
| US 11,912,776 | Chimeric Antigen Receptors Targeting B-Cell Maturation Antigen conveyed to Pfizer Inc. In force · High confidence | In force | High confidence | |
| US 10,259,876 | Chimeric Antigen Receptors Targeting Epidermal Growth Factor Receptor Variant III conveyed to Pfizer Inc. In force · High confidence | In force | High confidence | |
| US 12,152,081 | Chimeric Antigen Receptors Targeting CD70 conveyed to Pfizer Inc. In force · Medium confidence | In force | Medium confidence | |
| US 11,396,551 | Chimeric Antigen Receptors Targeting CD70 conveyed to Pfizer Inc. In force · Medium confidence | In force | Medium confidence | |
| US 12,296,012 | Chimeric Antigen Receptors Targeting FLT3 conveyed to Pfizer Inc. In force · High confidence | In force | High confidence |